Selected article for: "acute ARDS respiratory distress syndrome and cardiovascular disease"
Author: Vecchié, Alessandra; Batticciotto, Alberto; Tangianu, Flavio; Bonaventura, Aldo; Pennella, Benedetta; Abenante, Alessia; Corso, Rossana; Grazioli, Stefano; Mumoli, Nicola; Para, Ombretta; Maresca, Andrea Maria; Dalla Gasperina, Daniela; Dentali, Francesco
Title: High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study
  • Cord-id: irlout95
  • Document date: 2021_7_17
    • ID: irlout95
    Snippet: Low-dose dexamethasone reduces mortality in patients with coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS). We retrospectively analyzed the efficacy of high-dose dexamethasone in patients with COVID-19-related ARDS and evaluated factors affecting the composite outcome (death or invasive mechanical ventilation). From March 4th to April 1st 2020, 98 patients with COVID-19 pneumonia were included. Those who after at least 7 days from symptom onset presented a w
    Document: Low-dose dexamethasone reduces mortality in patients with coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS). We retrospectively analyzed the efficacy of high-dose dexamethasone in patients with COVID-19-related ARDS and evaluated factors affecting the composite outcome (death or invasive mechanical ventilation). From March 4th to April 1st 2020, 98 patients with COVID-19 pneumonia were included. Those who after at least 7 days from symptom onset presented a worsening of the respiratory function or of inflammatory biomarkers were started on intravenous high-dose dexamethasone (20 mg daily for 5 days, followed by 10 mg daily for 5 days). Most patients were males (62%) with a mean age of 69 years. Hypertension and cardiovascular disease (CVD) were prevalent. Following dexamethasone treatment, a significant improvement in PaO(2)/FiO(2) (277.41 [178.5–374.8] mmHg vs. 146.75 [93.62–231.16] mmHg, p < 0.001), PaO(2) (88.15 [76.62–112.0] mmHg vs. 65.65 [57.07–81.22] mmHg, p < 0.001), and SpO(2) (96 [95–98]% vs. 94 [90–96]%, p < 0.001) was observed. A concomitant decrease in C-reactive protein and ferritin levels was found (132.25 [82.27–186.5] mg/L vs. 7.3 [3.3–24.2] mg/L and 1169 [665–2056] ng/mL vs. 874.0 [569.5–1434] ng/mL, respectively; p < 0.001 for both vs. baseline). CVD was found to increase the risk of the composite outcome (RR 7.64, 95% CI 1.24–47.06, p = 0.028). In hospitalized patients with COVID-19-related ARDS, high-dose dexamethasone rapidly improves the clinical status and decreases inflammatory biomarkers. CVD was found to increase the risk of the composite outcome. These data support the importance of randomized clinical trials with high-dose dexamethasone in COVID-19 patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-021-02800-1.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute ards respiratory distress syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and low dose dexamethasone: 1
    • acute ards respiratory distress syndrome and low evidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute ards respiratory distress syndrome and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute ards respiratory distress syndrome and lung epithelial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome cause and admission death: 1, 2
    • acute ards respiratory distress syndrome cause and liver disease: 1
    • acute ards respiratory distress syndrome cause and low evidence: 1
    • acute ards respiratory distress syndrome cause and lung epithelial: 1, 2
    • acute phase and low evidence: 1
    • acute phase and low molecular: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and low molecular weight heparin: 1, 2, 3, 4, 5, 6
    • acute phase and low molecular weight heparin hydroxychloroquine: 1
    • acute phase and lung epithelial: 1, 2, 3, 4, 5
    • acute phase and mac spss statistics: 1
    • acute phase and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10